BioNTech Results Presentation Deck

Oncology: Multiple Phase 2 Trials Starting in 2021 15 product candidates in 18 clinical trials Drug Class 21 mRNA Antibodie S Cell Therapies Platform Three randomized Phase 2 trials Fix Vac (fixed combination of shared cancer antigens) iNeST (patient specific cancer antigen therapy) Next-Gen Checkpoint Immunomodulators CAR-T Cell Therapy Neoantigen-based T Cell Therapy Product Candidate BNT111 BNT112 BNT113 autogene cevumeran (BNT122) GEN 1046 (BNT311) GEN 1042 (BNT312) BNT211 BNT221 Indication (Targets) CPI-R/R melanoma prostate cancer HPV16+ head and neck cancer 1L melanoma adjuvant colorectal cancer solid tumors (PD-L1x4-1BB) solid tumors (CD40×4-1BB) solid tumors (CLDN6) advanced or metastatic melanoma Phase 1 Phase 2 ............ Near-Term Milestones FPD in Phase 2 in June 2021 FPD in Phase 2 in July 2021 Phase 2 to start in 2H 2021 (adjuvant CRC) Data update in 2H 2021 Data update in 2H 2021 Data update in 2H 2021 Planned randomized trial start in 2H 2021: CPI, checkpoint inhibitor; R/R, relapsed or refractory; Next-Gen, Next generation; HPV, Human Papilloma Virus; FPD, first patient dosed; 1L, first-line; CRC, colorectal cancer; CAR, chimeric antigen receptor; CLDN6, Claudin-6 ........ BIONTECH

View entire presentation